Inclusion Criteria:

          -  Age 18-60 years.

          -  Considered to be suitable intensive (cytotoxic) induction candidates.

          -  Has previously untreated, de novo, non-M3 AML with intermediate-risk disease
             (Intermediate-I or Intermediate-II) as defined by ELN criteria OR normal cytogenetics
             with mutated NPM1 without FLT3-ITD. Monoallelic CEBPA mutations are not considered
             favorable risk and are therefore eligible.

          -  Has undergone cytotoxic induction therapy

          -  In a morphologic complete remission with incomplete blood count recovery, or
             morphologic complete remission post-induction after no more than 2 induction cycles as
             defined by revised IWG criteria

          -  Patients at Washington University must be enrolled in HRPO# 201011766 ("Tissue
             Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases").This
             is not a requirement for secondary sites. However, secondary sites must provide
             informed consent forms that document that permission for whole genome, whole exome,
             and/or genome wide sequencing, and data sharing among institutions, was obtained.
             Because we will be also be sequencing non-diseased (normal) tissue, the informed
             consent forms must explicitly ask if patients wish to be informed, (or in the case of
             their death, their next-of-kin) if a deleterious mutation is identified in their
             non-diseased tissue, as this may be heritable.

          -  Women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control, abstinence) prior to study entry and for
             the duration of study participation. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she must inform her treating physician
             immediately.

          -  Able to understand and willing to sign an IRB approved written informed consent
             document.

          -  Willing to comply with the treatment assignment:

               -  Intent to proceed with HiDAC consolidation for LAM VAF <2.5%

               -  Intent to proceed with either HiDAC consolidation or allogeneic stem cell
                  transplantation, at the discretion of the treating physician, for LAM ≥2.5%

        Exclusion Criteria:

          -  Diagnosis acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); PML-RARA.

          -  Therapy-related AML (defined as occurrence of AML due to prior exposure to
             chemotherapy or radiation for malignancy).

          -  Secondary AML (defined as development of AML in patients with an antecedent
             hematological malignancy).

          -  Has a medical or psychosocial conditions that would prevent study compliance.

          -  Known seropositivity for or active viral infection with human immunodeficiency virus
             (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients who are
             seropositive because of hepatitis B vaccine are eligible.

          -  History of allergic reaction to compounds of similar chemical or biologic composition
             to cytarabine.

          -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative
             pregnancy test within 3 days of signing consent.